Find policies, billing codes, payers, states, and providers
CPT 78816: FDG PET/CT for Metabolic and Anatomical Tumor Imaging
Headline: PET/CT with FDG for oncology assessment — CPT code 78816
Lead: CPT code 78816 denotes PET/CT imaging performed after administration of the FDG radiotracer to visualize metabolic activity and accurately localize lesions. The combined PET and CT study improves detection of malignancy and guides staging, treatment planning, and surveillance.
What the code represents and why it matters: CPT code 78816 covers FDG PET/CT procedures that produce three-dimensional metabolic images fused with CT for anatomical detail. Nationally, PET/CT is a key diagnostic tool in oncology, influencing care pathways, surgical planning, and systemic therapy decisions. Accurate coding for PET/CT affects clinical documentation, utilization monitoring, and payer reimbursement policies.
Key payers covered: This analysis addresses coverage and billing considerations for Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
What readers will learn: The publication provides clinical context for FDG PET/CT use, benchmark comparisons across major payers, common coding relationships with related PET codes, and policy considerations that affect authorization and claims processing. Readers will find concise guidance on the clinical role of CPT code 78816, typical sites of service, and how it aligns with related PET-only imaging codes.
Customize your policy alerts
Sign up for cpt 78816 policy alerts
Get alerted when payer policies referencing 78816 are released or updated.
Monitor payer policy activity
Billing Code Overview
CPT code 78816 describes a diagnostic imaging procedure using positron emission tomography combined with computed tomography (PET/CT) after injection of the radiopharmaceutical tracer FDG (fluoro–deoxyglucose). The tracer is administered approximately one hour before imaging, is taken up by metabolically active cells, emits positrons that produce photons detected by the PET scanner, and is fused with CT images to provide precise anatomical localization of metabolic activity.
Service type: PET/CT imaging with FDG radiotracer for combined metabolic and anatomical evaluation
Typical site of service: Hospital outpatient imaging center or freestanding diagnostic imaging facility, with whole-body or limited-area imaging options depending on the clinical indication.
National Reimbursement Benchmarks
Nationwide, Medicare’s mean rate of $114 is far below the commercial BUCA aggregate mean of $2,029.10, highlighting a substantial public-versus-commercial gap for CPT 78816. Medicare’s central tendency sits tightly with its interquartile band from $110 to $116, reflecting consistent reimbursement across 47 localities, while BUCA’s median of $1,875.20 and mean near $2,029.10 indicate materially higher commercial reimbursement levels overall.
Examining dispersion via the P75–P25 spread: Blue Cross Blue Shield shows a wide spread of $1,333.30 ($3,248.50 − $1,915.20), UnitedHealth Group is also broad at $1,408.00 ($2,174.10 − $265.30), and BUCA’s spread is $1,362.20 ($2,554.70 − $1,192.50). The tightest interquartile ranges are Medicare at $6 ($116 − $110) and Aetna at $1,151.50 ($1,248.50 − $206.60), indicating relatively less variation for Medicare and comparatively moderate variation for Aetna among payers.